Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nifurtimox-Eflornithine Combination vs Standard Eflornithine for Trypanosoma Brucei Gambiense HAT
NCT00146627Phase 3Completed
- Sponsor
- Drugs for Neglected Diseases initiative
- Primary completion
- Jun 2008
- Modality
- Metabolically Activated Prodrugs
- Countries
- 2
01
Overview
Phase 3, randomised trial of nifurtimox in human African trypanosomiasis (HAT) (2 arms), sponsored by Drugs for Neglected Diseases initiative. Status: completed.
02
Drugs
nifurtimox
03
Conditions
human African trypanosomiasis (HAT)
Beyond the preview
Go deeper on NCT00146627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00146627.